# Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease

> **NCT00333788** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 233 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** Certolizumab pegol (CDP870)

## Key facts

- **NCT ID:** NCT00333788
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 233 (ACTUAL)
- **Last updated:** 2018-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00333788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00333788, "Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00333788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*